Chemotherapy now has an established role in the treatment of non-small cell lung cancer, with randomised evidence supporting a survival benefit in both advanced disease and the adjuvant setting. The availability of newer cytotoxic agents has not led to further improvement in outcome, and novel approaches are needed. Growth factor-mediated signalling pathways are frequently subverted in human cancers, so that physiological processes become abnormally regulated by oncogene products such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF). Drugs targeting EGFR and VEGF have already demonstrated improved survival compared with standard of care in lung cancer, and the evidence supporting the use of these and related agents is reviewed here. These newer agents are in general cytostatic rather than cytotoxic, so that clinical benefit can be associated with stable disease rather than with disease response alone, and the impact of this on imaging modalities used to assess response in trials and clinical practice is discussed.

Author

Fiona Kyle and James Spicer

Contact Details

Corresponding address:
James Spicer, Cancer Studies Division, King's College London, Guy's Campus,
Bermondsey Wing, Great Maze Pond, London, SE1 9RT, UK

Reference

ICIS Cancer Imaging Volume 8 Issue 1
DOI: 10.1102/1470-7330.2008.0027

Date Posted

25 November 2008

Print PDF

Size

710.22 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	2 seconds
ADSL 512Kb/s (Broadband):	11 seconds
64 Kb/s (ISDN):	1 minute 28 seconds
33.3 Kb/s (Typical Modem):	2 minutes 50 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 66356, London, E14 1GW. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.